RxDoctor Payments Data

Ricky Heirigs, MD

Cardiovascular Disease · North Platte, NENPI 1447346739

Payments from drug & device makers

$1,214in general payments, 2019–2025

Across 67 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$469
  • E.r. Squibb & Sons, L.L.C.$244
  • Amgen$105
  • Boehringer Ingelheim$88
  • Itamar Medical Inc$86
  • Boston Scientific$50
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$1,214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,214 in reported general payments places this provider in the 30th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$357,941
Medicare patients
969
Services billed
4,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$87,727
XareltoRivaroxaban117$82,856
Repatha SureclickEvolocumab50$26,647
JardianceEmpagliflozin18$12,378
MultaqDronedarone Hcl12$9,718
EntrestoSacubitril/Valsartan13$8,671
Atorvastatin Calcium247$2,521
Metoprolol Succinate226$2,223
Losartan Potassium154$2,038
ClopidogrelClopidogrel Bisulfate111$1,750
Flecainide Acetate27$1,730
Rosuvastatin Calcium111$1,592
Ezetimibe71$1,566
Propafenone Hcl ErPropafenone Hcl12$1,522
Amlodipine Besylate184$1,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$87,727135 claims
Johnson & JohnsonXarelto$38$82,856117 claims
Boehringer IngelheimJardiance$88$12,37818 claims
NovartisEntresto$469$8,67113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →